CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency... It was generated by HGS using the Abgenix XenoMouse technology.
- Mechanism
- Curator reviewed
The chemokine receptor CCR5 provides a portal of entry for HIV-1 and serves a target for potential new antiretroviral therapies. CCR5 monoclonal antibodies (mAb) and small-molecule CCR5 antagonists potently block HIV-1 entry in vitro, and controlled clinical trials have provided initial proof-of-concept for this mode of therapy.
- Primary indication
- Investigated for use/treatment in HIV infection.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CCR5 mAb, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account